Zealand Pharma obesity drug continues to phase II
Dapiglutide demonstrated weight loss of up to 4.3% of baseline body weight after four weeks of treatment.
by christian bundgaard & marketwire, translated by catherine brett
Novo Nordisk and Eli Lilly are battling it out on the billion-dollar obesity market, and Zealand Pharma wants in.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma CEO believes in firm's obesity efforts
For subscribers
Zealand Pharma issues almost USD 40m in shares
For subscribers
.jpg)
.jpg&w=384&q=75)
